(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.8%.
Corbus Pharmaceuticals Holdings's earnings in 2026 is -$101,903,000.On average, 12 Wall Street analysts forecast CRBP's earnings for 2026 to be -$102,951,769, with the lowest CRBP earnings forecast at -$117,138,607, and the highest CRBP earnings forecast at -$82,391,974. On average, 11 Wall Street analysts forecast CRBP's earnings for 2027 to be -$107,930,217, with the lowest CRBP earnings forecast at -$130,785,823, and the highest CRBP earnings forecast at -$52,598,646.
In 2028, CRBP is forecast to generate -$112,889,325 in earnings, with the lowest earnings forecast at -$139,883,967 and the highest earnings forecast at -$63,768,243.